Powered by

Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors; Ms. Smith brings significant experience in biotech leadership and genetic diseases

Jun 04, 2020 - Business Wire
Board and Executive Moves

Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Julie Anne Smith to its Board of Directors. Ms. Smith has also been appointed to the Compensation Committee of the Board of Directors. Ms. Smith will replace Samuel Hall, Ph.D., whose term on the Board of Directors expired.

"Julie brings more than two decades of experience in...